There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
CNN
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage. Liraglutide, sold under the brand name Victoza for diabetes, is an earlier iteration in the same class as semaglutide, the active ingredient in Ozempic. Both are sold by Danish drug giant Novo Nordisk. The generic liraglutide is sold by Hikma Pharmaceuticals USA, and a spokesman told CNN by email that the company expects to make the drug available nationwide before the end of the year. The company didn’t disclose the planned price of the generic, noting only that it “will cost less than branded Victoza.” The branded drug costs between $500 and $815 per package, depending on the dosage, before discounts or insurance, according to Novo Nordisk, which also sells a version of liraglutide approved for obesity, called Saxenda. “There are many people on this drug, and they will benefit by another generic version of it,” Dr. Harlan Krumholz, a cardiologist at Yale University and Yale New Haven Hospital, told CNN by email. But, Krumholz noted, the newer GLP-1 drugs, which are given as weekly injections instead of daily ones, have shown stronger benefits, especially for patients with obesity – and those aren’t yet available as generics.
With the release of “The Bride!” we asked scholars, film curators and experts in Mary Shelley’s work why so few women have tackled the Frankenstein story — and the impact that has on how we make sense of the 200-year-old tale.
In front of the Louvre Pyramid, Eileen Gu stepped out this week wearing a set of diaphanous wings — a fitting ensemble for an Olympic athlete whose sport sends her airborne.
Meagan Johnson recently spent four days calling dozens of pharmacies around Austin, Texas, trying to fill a prescription for her son, Jack.
Evidence is mounting that the wildly popular weight-loss medicines known as GLP-1s may also hold potential for treating addiction, and the field may be on the verge of obtaining desperately needed answers through more study.
Known for her blistering pace and powerful shots, the soccer player is having a Barbie made in her likeness as the toymaker names her as role model of the year.
The Screen Actors Guild Awards are back with a new name — and a thematic dress code.
There’s growing concern that the US Department of Health and Human Services is abandoning the US Preventive Services Task Force – or pushing it into “quiet paralysis.”
An international meeting to determine the status of measles elimination in the United States has been delayed seven months, from its original date in mid-April until sometime in November.
When she was in her 40s Jenny Teeters had a serious secret drinking problem, but, she says, her success hid it exceptionally well for years. At one point she managed a high six-figure tech job, raised two teenage girls, finished her MBA, and taught Zumba in her spare time and somehow she did it all while intoxicated.But she got to a place where she knew she needed help, and like with what a new study found, she found what finally made her sobriety stick was developing a newfound faith in a higher power.
Gucci’s new designer Demna embraces the technology, with uneven results.
Next winter Burberry wants you out on the town, whatever the weather.
The US has recorded more than 1,100 measles cases so far this year, according to data published Friday by the US Centers for Disease Control and Prevention. It’s a troubling milestone that has many in public health bracing for the worst.